Skip to main content

Hypercalcemia of Malignancy

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
zoledronic acidPhase 31 trial
Active Trials
NCT00003884Completed600Est. Jan 2001
Biocorp
BiocorpFrance - Issoire
1 program
1
JMT103Phase 1/21 trial
Active Trials
NCT04198480Unknown17Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sandozzoledronic acid
BiocorpJMT103

Clinical Trials (2)

Total enrollment: 617 patients across 2 trials

NCT00003884Sandozzoledronic acid

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Start: Aug 1998Est. completion: Jan 2001600 patients
Phase 3Completed

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Start: Jan 2020Est. completion: Dec 202117 patients
Phase 1/2Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.